Influenza vaccination for patients with complicated nephrotic syndrome treated with rituximab

Influenza vaccination for patients with complicated nephrotic syndrome treated with rituximab - Influenza vaccination for patients with nephrotic syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024646

Enrollment

Registered

2016-10-31

Start date

2016-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complicated nephrotic syndrome treated with rituximab

Interventions

Influenza vaccines

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with complicated nephrotic syndrome who has been treated with rituximab in one year.

Exclusion criteria

Exclusion criteria: Patients who do not agree for the entry of the study.

Design outcomes

Primary

Measure	Time frame
MFI(mean fold increase) of GMT(geometric mean titer) of one month and three months after vaccination compared with that before vaccination.	—

Secondary

Measure	Time frame
1) Relationship between B-cell counts and MFI. 2) Relationship between period after the rituximab treatment and MFI. 3) Seroconversion rate of one month and three months after vaccination compared with that before vaccination. 4) Relationship between B-cell counts and seroconversion rate. 5) Relationship between period after the rituximab treatment and seroconversion rate. 6) Seroprotection rate of one month and three months after vaccination. 7) Relationship between B-cell counts and seroprotection rate. 8) Relationship between period after the rituximab treatment and seroprotection rate. 9) Relapses of nephrotic syndrome after vaccination. 10) Adverse events after vaccination. 11) Occurence of influenza infections. 12) Occurence of life-threatening influenza infections.	—

Measure

Time frame

1) Relationship between B-cell counts and MFI. 2) Relationship between period after the rituximab treatment and MFI. 3) Seroconversion rate of one month and three months after vaccination compared with that before vaccination. 4) Relationship between B-cell counts and seroconversion rate. 5) Relationship between period after the rituximab treatment and seroconversion rate. 6) Seroprotection rate of one month and three months after vaccination. 7) Relationship between B-cell counts and seroprotection rate. 8) Relationship between period after the rituximab treatment and seroprotection rate. 9) Relapses of nephrotic syndrome after vaccination. 10) Adverse events after vaccination. 11) Occurence of influenza infections. 12) Occurence of life-threatening influenza infections.

—

Countries

Japan

Contacts

Public ContactKoichi Kamei

National Center for Child Health and Development Division of Nephrology and Rheumatology

kamei-k@ncchd.go.jp03-5494-7128

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026